Cingulate Inc., a NASDAQ-listed biopharmaceutical company, announced the adjournment of its Special Meeting of Stockholders originally scheduled for August 23, 2024. The postponement was due to the lack of a quorum, as an insufficient number of shares were present or represented by proxy to conduct the meeting. The Board of Directors has reaffirmed its belief that the proposals outlined in the proxy statement are in the best interests of the stockholders. The adjourned meeting is now rescheduled for 11:00 a.m. Central Time on August 28, 2024, and will be accessible via a specified URL. Stockholders of record as of June 28, 2024, are encouraged to vote for all proposals ahead of the new meeting date by calling a toll-free number or voting online. Cingulate specializes in developing pharmaceutical products using its proprietary Precision Timed Release drug delivery platform, with a current focus on treating ADHD and exploring applications for anxiety disorders.

Cingulate Inc., a NASDAQ-listed biopharmaceutical company, announced the adjournment of its Special Meeting of Stockholders originally scheduled for August 23, 2024. The postponement was due to the lack of a quorum, as an insufficient number of shares were present or represented by proxy to conduct the meeting. The Board of Directors has reaffirmed its belief that the proposals outlined in the proxy statement are in the best interests of the stockholders. The adjourned meeting is now rescheduled for 11:00 a.m. Central Time on August 28, 2024, and will be accessible via a specified URL. Stockholders of record as of June 28, 2024, are encouraged to vote for all proposals ahead of the new meeting date by calling a toll-free number or voting online. Cingulate specializes in developing pharmaceutical products using its proprietary Precision Timed Release drug delivery platform, with a current focus on treating ADHD and exploring applications for anxiety disorders.